TNNI3 and ocular melanoma: At week 20, in patients receiving fixed-dose and titrated OM, there was a small increased concentration of circulating cTnI (0.001 ng/mL and 0.006 ng/mL, respectively, compared with no change seen in the placebo group) that did not correlate with the maximum plasma concentration of OM (r2 = 0.017) [62••].